Clinical TrialsDrugs (Pharmaceuticals)PancreasPancreatic CancerResearchTumors

F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

OMEGAZEPRIME News
This story was selected and curated by our editorial team in the Clinical Trials category. Published on August 26, 2026 • Originally reported by Gina Kolata and Rebecca Robbins. OMEGAZEPRIME provides independent news coverage and analysis for our readers. Stay informed with the latest developments.
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
OMEGAZEPRIME News — For more stories and analysis, visit omegazeprime.com

SUPPORT OMEGAZEPRIME

Help us keep delivering breaking news and world updates.

PayPalShop OMEGAZEPIX